IMMX — Immix Biopharma, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1873835 ·
Last close
$7.04
Market Cap
$590.04M
52W High
$15.10
52W Low
$3.78
ADV30
1,186,717
Next earnings
2026-11-12
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -15,945,871 -13,927,180 345,948,808 320,315,143 10,893,546
Jun 2026 0 — -12,456,343 -11,557,002 239,108,896 225,491,985 10,192,343
Mar 2026 0 — -10,803,855 -10,086,687 95,816,057 79,250,163 11,452,001
Dec 2025 0 — -10,893,276 -10,687,830 104,840,341 93,928,566 11,044,171

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-38,498,081
Investing CF
$-9,149,614
Financing CF
$261,522,180
CapEx
$-591,111
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.82
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-126,106,973
Inventory
—
Receivables
$0
ST Investments
$6,615,168
EBIT TTM
$-41,815,983
Pretax Income TTM
$-39,883,901
Interest Exp TTM
—
Analysts
8

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -29,956,415 -29,438,613 104,840,341 11,044,171 93,796,170 -23,930,304
Dec 2024 0 -22,674,680 -21,613,376 22,947,872 9,696,669 13,251,203 -14,595,102
Dec 2023 0 -16,141,113 -15,426,048 19,925,160 3,721,783 16,405,114 -11,371,438
Dec 2022 0 -8,218,948 -8,229,713 14,908,101 1,748,296 13,159,805 -7,408,303
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$1,932,082
NetIncome TTM
$-39,917,211
OpCashFlow TTM
—
Assets (Latest)
$239,108,896
Forward EPS
$-0.94

Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $5.00 · spot: $7.04 · call volume: 93 · put volume: 1
Expected Move to 2027-02-19: ±$3.40 (48.30%) — implied range $3.64 – $10.44 · ATM straddle on $7.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
GERN GERON CORP $588.19M $0.91 —
DSGN Design Therapeutics, Inc. $596.82M $9.32 —
AVBP ArriVent BioPharma, Inc. $582.40M $11.26 —
BCAX Bicara Therapeutics Inc. $605.45M $9.12 —
ALMS ALUMIS INC. $562.12M $4.33 —

News headlines (Yahoo Finance, 1h cache)

Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
2026-11-12 21:15 · Yahoo
Immix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026
2026-11-04 14:15 · Yahoo
Immix Biopharma (IMMX) Stock Sees Modest Fair Value Lift After Split Analyst Revisions
2026-10-21 04:29 · Yahoo
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
2026-10-05 12:45 · Yahoo
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study
2026-10-05 03:02 · Yahoo
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
2026-09-30 21:15 · Yahoo
BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock
2026-09-29 17:48 · Yahoo
Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 Trial
2026-09-29 13:34 · Yahoo
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Po
2026-09-29 11:00 · Yahoo
Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run
2026-07-21 21:17 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.